键凯科技(688356) - 2024 Q3 - 季度财报(更正)

Correction Announcement Regarding the Q3 2024 Report The company issued a correction to its Q3 2024 report, clarifying that the adjustments do not impact overall financial performance and apologizing for any inconvenience Overview of Correction Matters The company issued a correction to its Q3 2024 report, clarifying that these adjustments do not affect the company's overall financial position or operating results for the period - The company disclosed its Q3 2024 Report on October 31, 2024, and subsequently issued a correction announcement due to errors found in certain data listings[1] - This correction will not impact the company's Q3 2024 financial position or operating performance[1] - The company sincerely apologizes for any inconvenience caused by this correction and pledges to strengthen audit procedures to improve information disclosure quality[3] Specific Correction Details Core corrections adjust year-to-date foreign product sales growth rates for medical devices and pharmaceuticals, with total revenue remaining unchanged - From the beginning of the year to the end of the reporting period, the company achieved operating revenue of RMB 186 million, a year-on-year decrease of 23.97%; total product sales revenue was RMB 181.63 million, a year-on-year decrease of 19.99%. These core figures remain unchanged after the correction[1][2][3] Corrected Year-on-Year Changes in Foreign Product Sales | Item | Before Correction | After Correction | | :--- | :--- | :--- | | YoY Change in Foreign Medical Device Sales Revenue | -28.52% | -32.80% | | YoY Change in Foreign Pharmaceutical Client Sales Revenue | +112.98% | +204.69% |